Industry in brief | Reckitt Benckiser, Cefaly, BioGaia

Industry in brief | Reckitt Benckiser, Cefaly, BioGaia

13 October 2020 - Deborah Wilkes

Reckitt Benckiser (RB) has made a further investment in Your.MD, Cefaly Technology’s migraine treatment device is now available OTC in the US, and BioGaia has issued a sales warning.

RB makes further investment in Your.MD

RB has made a further investment in Your.MD, the digital health company behind the free self-care app Healthily.

RB led a USD30 million Series A round of investment which the company says will help Your.MD “expand its reach across markets including the UK, India and the US”.

The move follows RB’s “strategic investment and partnership” with Your.MD announced in 2019 (click here to read the News story).

In September, Healthily introduced its first co-branded app in India with RB’s Dettol brand.

RB said Your.MD had reported user growth of 350% over the past 12 months.

Your.MD’s mission is to “help everyone in the world find their health through informed self-care”.

Cefaly Dual available OTC in the US

Cefaly Technology said the US Food and Drug Administration (FDA) had cleared its Cefaly Dual migraine treatment device for OTC sale.

The medical device was previously only available in the US with a prescription.

Cefaly Dual is an external trigeminal nerve stimulator device that is placed on the forehead. It offers two treatment options: a 60-minute “acute” setting for pain relief at the onset of a migraine; and a 20-minute “prevent” setting for daily use to help prevent future episodes.

The product can be purchased from the brand website.

BioGaia issues sales warning

BioGaia says its sales and earnings in the third and fourth quarter of 2020 will be “negatively affected” by the COVID-19 pandemic.

The Swedish probiotics specialist estimates that sales in the third quarter of 2020 will decrease by around 21% to SEK132 million (USD15 million) and operating profit will drop by around 45% to SEK27 million.

The company says it is too early to comment on sales for the fourth quarter of 2020 but it estimates they will be lower than expected.

Sales in most countries depend on doctors and pharmacists recommending their patients to use BioGaia’s products, notes the company, adding that the salesforces of its distributors had not been able to visit doctors and pharmacy staff in the same way as before the COVID-19 pandemic.

According to chief executive officer Isabelle Ducellier, the decrease in sales is “related to COVID-19” and will “not affect long-term expectations”. She added that the company was reviewing its costs.

Click tags below for more information on topics:

RB BioGaia

Back to Industry News

Share this page: